Watch this insightful webinar today to understand the impact of the IRA on pricing negotiations in the pharmaceutical industry.
The signing of the Inflation Reduction Act (IRA) in 2022 represented one of the most significant landscape changes to the US healthcare ecosystem over the past decade. In particular, the provision authorizing Centers for Medicare and Medicaid Services (CMS) to negotiate drug prices has had a major impact on pharmaceutical manufacturers.
On August 15, 2024, CMS released the maximum fair price (MFP) for the first 10 drugs selected for price negotiations. However, the detailed explanation of the rationale for the negotiated prices will not be released until March 1, 2025.
The expert panel has investigated the CMS policy guidance around evidence considered while determining MFPs and will offer perspectives around evidence strategies that could help manufacturers demonstrate true product value during Medicare price negotiations.
By attending this webinar, attendees will:
- Gain an understanding of CMS’ initial policy guidance on evidence leveraged for supporting negotiations with manufacturers and determining MFP
- Explore strategies for developing robust evidence packages to be prepared for future Medicare price negotiations